Third Affiliated Hospital, Sun Yat-Sen University: Carcinoma, Hepatocellular trials

The registry lists 10 Carcinoma, Hepatocellular studies with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 2Phase 3 1Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 TrialNot yet recruitingNCT07543783Phase 2
• Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07543510Not applicable
• Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07281664Not applicable
• TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTTRecruitingNCT05984511Not applicable
• Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCCRecruitingNCT05484908Not applicable
• TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3
• Oral Vitamin D Treatment for the Prevention of Hepatocellular CarcinomaNot yet recruitingNCT02779465Phase 4
• Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver TransplantationStatus unknownNCT04564313Phase 1
• Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control TrialStatus unknownNCT02817685
• Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver TransplantationStatus unknownNCT02399735Phase 1